Author Of 1 Presentation
P0098 - Investigation of biomarkers in Multiple Sclerosis and Neuromyelitis Optica Spectrum Disorders (ID 1302)
Abstract
Background
In neuroimmunology; biomarkers have been determined as having a pivotal role. Among them, Neurofilament Light Chain (NfL), Glial Fibrillary Acidic Protein (GFAP), Interleukin-6 (IL-6), Osteopontin, Growth-associated protein 43 (GAP-43) have been examined for different central nervous system autoimmune disorders. It has been shown that each of them has a potential role for a different immunopathogenesis.
Objectives
In our study, we aimed to evaulate NfL, GFAP, Osteopontin, IL-6, GAP-43 in different subgroups of Multiple Sclerosis(MS). Relapsing-Remitting MS(RRMS)(n=38), Secondary-Progressive MS(SPMS)(n=16), Primary-Progressive MS(PPMS)(n=8), were included in this study. The samples from aquaporin-4(AQP4)-Ab-positive NMOSD(n=7), Myelin Oligodendrocyte Glycoprotein(MOG)-Ab-positive(n=9) patients and healthy controls(HC)(n=20) were also studied. All biomarkers were evaluated both in serum and cerebrospinal fluid (CSF).
Methods
Serum (n=98) and available CSF (n=20)(paired with serum,only MS subtypes) samples have used this cross-sectional study. For measuring NfL and GFAP concentrations in sera and CSF samples, we used SIMOA technology and assays on the Quanterix SIMOA HD-X ANALYZER. IL-6 measurements were performed on the Roche Cobas e-411 analyzer with the electrochemiluminescence method. Osteopontin and GAP-43 levels determined with the ELISA assays. Clinical and radiological data at sampling were collected for each case.
Results
We observed a significant positive correlation between serum NFL,GFAP and CSF NFL,GFAP levels in MS patiens(NfL,p=0,001,rho=0,686; GFAP,p=0,006,rS=0,594). For serum samples, there was a very strong positive correlation between treatment-naive GFAP and treatment-naive NFL levels in MS patients (p<0,001, rS=0,828). Additionaly, we have found negative correlation between serum IL-6 and GFAP levels in MS patients (p<0,01, rS =-0,356). Also there was a negative correlation between serum IL-6 and NfL levels in MS patients (p<0,01, rS =-0,422). When compared with HC, there was a significant incrase in terms of serum IL-6 levels in central neuroimmunological disorders(p<0,001).Mean value of AQP4-Ab-positive NMOSD serum GFAP levels(111,7±29,39 pg/mL) were signififantly higher than MOG-Ab-positive serum GFAP levels(80,39±32,53 pg/mL)(p<0,05). MOG-Ab-positive serum IL-6 mean values(42±52,17 pg/mL) were found to be higher than AQP4-Ab-positive NMOSD group(6,17±4,36 pg/mL)(p<0,05).
Conclusions
NfL and GFAP are certainly promising biomarkers in MS patients. NMOSD and MOG-Ab-positive patients have to be assessed in prospective studies that have a large number of patients. Our study is the first that Single Molecule Array (SIMOA) technology has been used in Turkey to evaluate NfL, GFAP levels both in serum and CSF levels.